Our Take
Regulatory clearance for a delivery mechanism is not a clinical advance; it is a convenience claim that still requires evidence of uptake and practitioner preference in real anaphylaxis events.
Why it matters
Needle-free adrenaline delivery removes a friction point in paediatric emergency response, but only if hospitals, clinics, and parents actually switch from traditional auto-injectors. Approval is necessary, not sufficient.
Do this week
Procurement leads: contact your NHS trust's pharmacy and paediatric teams to understand whether EURneffy will be stocked as a first-line or backup option before the next budget cycle.
MHRA clears needle-free adrenaline for UK children
ALK Abelló has secured marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for EURneffy 1mg, a needle-free adrenaline auto-injector for children experiencing anaphylaxis. The device delivers adrenaline without a traditional needle, using an alternative injection mechanism.
EURneffy is intended for use in acute anaphylaxis management in the paediatric population. The MHRA approval is based on the company's demonstration of safety and efficacy for the needle-free delivery method.
Needle anxiety is real; adoption barriers are bigger
Needle phobia affects a significant portion of children and adolescents, and fear can delay or prevent self-administration of adrenaline during an anaphylactic event. A needle-free option lowers that barrier in theory.
However, regulatory approval does not equal clinical adoption. Hospitals and community clinics must stock the device, train staff on its use, and ensure parents and children know how to use it correctly. Cost parity or payer coverage relative to existing auto-injectors will determine whether EURneffy becomes a standard stock item or remains a specialised alternative. Distribution, reimbursement, and training infrastructure are separate from approval and will take months to establish.
Hospitals and GPs: plan for supply chain lag
MHRA approval does not guarantee immediate availability on NHS formularies or in primary care surgeries. Procurement cycles, budget negotiations, and supply agreements with ALK typically follow regulatory clearance by weeks or months. Clinical leads should anticipate questions from parents about needle-free options and from nursing staff about device training. Begin conversations with your medicines management team now to understand whether EURneffy will be offered and under what conditions.